Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.
Apr 2, 2012
0
0
A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable ...
Feb 1, 2012
0
0
Focus On Lyme, an initiative sponsored by the Leadership Children's Foundation of Gilbert, Ariz., has donated $75,000 to the Translational Genomics Research Institute (TGen) to support research into the development of a quick, ...
Jul 20, 2015
0
70
Using a basic genetic difference between men and women, the Translational Genomics Research Institute (TGen) has uncovered a way to track down the source of a neurological disorder in a young girl.
Dec 12, 2014
0
0
Scientists at the Translational Genomics Research Institute (TGen), using state-of-the-art genetic technology, have discovered the likely cause of a child's rare type of severe muscle weakness.
Apr 9, 2015
0
18
The Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing (WGS) of a rare nasal tract cancer called olfactory neuroblastoma ...
May 23, 2012
0
0
Researchers at the Translational Genomics Research Institute (TGen) have identified a genetic mutation associated with the appearance of premature aging and severe loss of body fat in children.
Jul 16, 2015
0
37
An international team of scientists, including those at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has devised a tool that could help design more successful clinical trials for new ...
Dec 20, 2021
0
22
Taking a page from Chinese herbal medicine, Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) today initiated the first-in-human clinical trial for pancreatic cancer patients using a compound ...
Sep 12, 2013
0
1
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, ...
Apr 4, 2012
0
0
